KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $4.9 billion.

  • Alnylam Pharmaceuticals' Liabilities and Shareholders Equity rose 1537.73% to $4.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $17.9 billion, marking a year-over-year increase of 1261.92%. This contributed to the annual value of $4.2 billion for FY2024, which is 1070.8% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Liabilities and Shareholders Equity stood at $4.9 billion for Q3 2025, which was up 1537.73% from $4.6 billion recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Liabilities and Shareholders Equity registered a high of $4.9 billion during Q3 2025, and its lowest value of $3.3 billion during Q1 2021.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Liabilities and Shareholders Equity value was $3.6 billion (recorded in 2021), while the average stood at $3.8 billion.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Liabilities and Shareholders Equity soared by 4279.85% in 2021 and then crashed by 510.09% in 2022.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Liabilities and Shareholders Equity stood at $3.6 billion in 2021, then dropped by 2.66% to $3.5 billion in 2022, then grew by 7.99% to $3.8 billion in 2023, then rose by 10.71% to $4.2 billion in 2024, then grew by 14.43% to $4.9 billion in 2025.
  • Its last three reported values are $4.9 billion in Q3 2025, $4.6 billion for Q2 2025, and $4.2 billion during Q1 2025.